Skip to main content

Qulipta News

U.S. FDA Approves Qulipta (atogepant) for Adults With Chronic Migraine

NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of Qulipta (atogepant) ...

FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine

NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Chronic Migraine, Migraine Prevention, Migraine Prophylaxis

Qulipta patient information at Drugs.com